Difference between revisions of "CNS melanoma"
Jump to navigation
Jump to search
Tmcgranahan (talk | contribs) Tag: visualeditor |
|||
Line 1: | Line 1: | ||
{| class="wikitable" style="text-align:center; width:100%;" | {| class="wikitable" style="text-align:center; width:100%;" | ||
− | !colspan="4" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editors''' | + | ! colspan="4" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Section editors''' |
|- | |- | ||
− | |style="background-color:#F0F0F0; width:15%"|[[File:SeemaNagpal.jpg|frameless|upright=0.3|center]] | + | | style="background-color:#F0F0F0; width:15%" |[[File:SeemaNagpal.jpg|frameless|upright=0.3|center]] |
− | |style="width:35%" |<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Stanford University<br>Palo Alto, CA</big> | + | | style="width:35%" |<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Stanford University<br>Palo Alto, CA</big> |
− | |style="background-color:#F0F0F0; width:15%"|[[File:Bethbuchbinder.jpg|frameless|upright=0.3|center]] | + | | style="background-color:#F0F0F0; width:15%" |[[File:Bethbuchbinder.jpg|frameless|upright=0.3|center]] |
− | |style="width:35%" |<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Dana-Farber Cancer Institute<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn] | + | | style="width:35%" |<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Dana-Farber Cancer Institute<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn] |
|- | |- | ||
|} | |} | ||
Line 17: | Line 17: | ||
=Guidelines= | =Guidelines= | ||
==EANO/ESMO== | ==EANO/ESMO== | ||
+ | |||
*'''2017:''' Le Rhun et al. [https://www.esmo.org/Guidelines/Neuro-Oncology/EANO-ESMO-Leptomeningeal-Metastasis-Clinical-Practice-Guidelines EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours] | *'''2017:''' Le Rhun et al. [https://www.esmo.org/Guidelines/Neuro-Oncology/EANO-ESMO-Leptomeningeal-Metastasis-Clinical-Practice-Guidelines EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours] | ||
+ | |||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
+ | |||
*[https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf NCCN Guidelines - Central Nervous System Cancers] | *[https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf NCCN Guidelines - Central Nervous System Cancers] | ||
Line 33: | Line 36: | ||
|} | |} | ||
{| class="wikitable" style="width: 75%; text-align:center;" | {| class="wikitable" style="width: 75%; text-align:center;" | ||
− | !style="width: 33%"|Study | + | ! style="width: 33%" |Study |
− | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | + | ! style="width: 33%" |[[Levels_of_Evidence#Efficacy|Efficacy]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70431-X/fulltext Long et al. 2012 (BREAK-MB)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70431-X/fulltext Long et al. 2012 (BREAK-MB)] | ||
− | |style="background-color:#91cf61"|Phase II (RT) | + | | style="background-color:#91cf61" |Phase II (RT) |
| style="background-color:#8c6bb1" |ORR: 31-39% | | style="background-color:#8c6bb1" |ORR: 31-39% | ||
|- | |- | ||
|} | |} | ||
+ | |||
+ | ====== Biomarker: ====== | ||
+ | |||
+ | * [[Biomarkers#Genes#BRAF|BRAF]] V600 mutant | ||
+ | * Study Inclusion criteria: Val600Glu or Val600Lys | ||
+ | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | *[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | ||
Line 48: | Line 58: | ||
===References=== | ===References=== | ||
− | # '''BREAK-MB:''' Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13(11):1087-95. Epub 2012 Oct 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70431-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23051966 PubMed] | + | |
+ | #'''BREAK-MB:''' Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13(11):1087-95. Epub 2012 Oct 8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70431-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23051966 PubMed] | ||
==Dabrafenib & Trametinib {{#subobject:7d3694|Regimen=1}}== | ==Dabrafenib & Trametinib {{#subobject:7d3694|Regimen=1}}== | ||
Line 61: | Line 72: | ||
|} | |} | ||
{| class="wikitable" style="width: 75%; text-align:center;" | {| class="wikitable" style="width: 75%; text-align:center;" | ||
− | !style="width: 33%"|Study | + | ! style="width: 33%" |Study |
− | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | + | ! style="width: 33%" |[[Levels_of_Evidence#Efficacy|Efficacy]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30429-1/fulltext Davies et al. 2017 (COMBI-MB)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30429-1/fulltext Davies et al. 2017 (COMBI-MB)] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
| style="background-color:#9ebcda" |ORR: 44-59% | | style="background-color:#9ebcda" |ORR: 44-59% | ||
|- | |- | ||
|} | |} | ||
+ | |||
+ | ====== Biomarkers ====== | ||
+ | |||
+ | * ''[[Biomarkers#Genes#BRAF|BRAF]]'' V600 mutant | ||
+ | * Clinical Trial Inclusion: BRAF V600 E/K/D/R | ||
+ | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | *[[Dabrafenib (Tafinlar)]] 150 mg PO twice per day | ||
*[[Trametinib (Mekinist)]] 2 mg PO once per day | *[[Trametinib (Mekinist)]] 2 mg PO once per day | ||
Line 77: | Line 95: | ||
===References=== | ===References=== | ||
− | # '''COMBI-MB:''' Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18(7):863-873. Epub 2017 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30429-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28592387 PubMed] | + | |
+ | #'''COMBI-MB:''' Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18(7):863-873. Epub 2017 Jun 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30429-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28592387 PubMed] | ||
==Ipilimumab & Nivolumab {{#subobject:28103f|Regimen=1}}== | ==Ipilimumab & Nivolumab {{#subobject:28103f|Regimen=1}}== | ||
Line 86: | Line 105: | ||
===Regimen {{#subobject:6cf5ae|Variant=1}}=== | ===Regimen {{#subobject:6cf5ae|Variant=1}}=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 25%"|Comparator | + | ! style="width: 25%" |Comparator |
− | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30139-6/fulltext Long et al. 2018 (ANZMTG 01.14)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30139-6/fulltext Long et al. 2018 (ANZMTG 01.14)] | ||
− | |style="background-color:#1a9851"|Randomized Phase II (E-esc) | + | | style="background-color:#1a9851" |Randomized Phase II (E-esc) |
|Nivolumab | |Nivolumab | ||
| style="background-color:#ffffbf" |Did not meet primary endpoint of intracranial response from week 12 | | style="background-color:#ffffbf" |Did not meet primary endpoint of intracranial response from week 12 | ||
Line 98: | Line 117: | ||
|} | |} | ||
====Immunotherapy, part 1==== | ====Immunotherapy, part 1==== | ||
+ | |||
*[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1 | *[[Ipilimumab (Yervoy)]] 3 mg/kg IV once on day 1 | ||
*[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1 | *[[Nivolumab (Opdivo)]] 1 mg/kg IV once on day 1 | ||
Line 104: | Line 124: | ||
====Immunotherapy, part 2==== | ====Immunotherapy, part 2==== | ||
+ | |||
*[[Nivolumab (Opdivo)]] 3 mg/kg IV over 60 minutes once on day 1 | *[[Nivolumab (Opdivo)]] 3 mg/kg IV over 60 minutes once on day 1 | ||
Line 109: | Line 130: | ||
===References=== | ===References=== | ||
− | # '''ANZMTG 01.14:''' Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30139-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29602646 PubMed] | + | |
+ | #'''ANZMTG 01.14:''' Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30139-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29602646 PubMed] | ||
==Vemurafenib monotherapy {{#subobject:28825f|Regimen=1}}== | ==Vemurafenib monotherapy {{#subobject:28825f|Regimen=1}}== | ||
Line 118: | Line 140: | ||
===Regimen {{#subobject:6cfyyz|Variant=1}}=== | ===Regimen {{#subobject:6cfyyz|Variant=1}}=== | ||
{| class="wikitable" style="width: 50%; text-align:center;" | {| class="wikitable" style="width: 50%; text-align:center;" | ||
− | !style="width: 50%"|Study | + | ! style="width: 50%" |Study |
− | !style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://academic.oup.com/annonc/article/28/3/634/2716532 McArthur et al. 2017] | |[https://academic.oup.com/annonc/article/28/3/634/2716532 McArthur et al. 2017] | ||
Line 125: | Line 147: | ||
|- | |- | ||
|} | |} | ||
+ | |||
+ | ====== Biomarker ====== | ||
+ | |||
+ | * [[Biomarkers#Genes#BRAF|BRAFV600]] mutant | ||
+ | |||
====Chemotherapy==== | ====Chemotherapy==== | ||
+ | |||
*[[Vemurafenib (Zelboraf)]] | *[[Vemurafenib (Zelboraf)]] | ||
===References=== | ===References=== | ||
− | # McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol. 2017 Mar 1;28(3):634-641. [https://academic.oup.com/annonc/article/28/3/634/2716532 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27993793 PubMed] | + | |
+ | #McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol. 2017 Mar 1;28(3):634-641. [https://academic.oup.com/annonc/article/28/3/634/2716532 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27993793 PubMed] | ||
[[Category:CNS melanoma regimens]] | [[Category:CNS melanoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:CNS cancers]] | [[Category:CNS cancers]] |
Revision as of 00:07, 9 January 2020
Section editors | |||
---|---|---|---|
Seema Nagpal, MD Stanford University Palo Alto, CA |
Elizabeth Buchbinder, MD Dana-Farber Cancer Institute Boston, MA |
5 regimens on this page
5 variants on this page
|
Note: these are CNS-specific regimens, please see the main melanoma page for other regimens.
Guidelines
EANO/ESMO
- 2017: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
NCCN
All lines of therapy
Dabrafenib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Efficacy |
---|---|---|
Long et al. 2012 (BREAK-MB) | Phase II (RT) | ORR: 31-39% |
Biomarker:
- BRAF V600 mutant
- Study Inclusion criteria: Val600Glu or Val600Lys
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
Continued indefinitely
References
- BREAK-MB: Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov;13(11):1087-95. Epub 2012 Oct 8. link to original article contains verified protocol PubMed
Dabrafenib & Trametinib
back to top |
Regimen
FDA-recommended dose |
Study | Evidence | Efficacy |
---|---|---|
Davies et al. 2017 (COMBI-MB) | Phase II | ORR: 44-59% |
Biomarkers
- BRAF V600 mutant
- Clinical Trial Inclusion: BRAF V600 E/K/D/R
Chemotherapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- COMBI-MB: Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 Jul;18(7):863-873. Epub 2017 Jun 4. link to original article contains protocol PubMed
Ipilimumab & Nivolumab
back to top |
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Long et al. 2018 (ANZMTG 01.14) | Randomized Phase II (E-esc) | Nivolumab | Did not meet primary endpoint of intracranial response from week 12 |
Immunotherapy, part 1
- Ipilimumab (Yervoy) 3 mg/kg IV once on day 1
- Nivolumab (Opdivo) 1 mg/kg IV once on day 1
21-day cycle for 4 cycles, followed by:
Immunotherapy, part 2
- Nivolumab (Opdivo) 3 mg/kg IV over 60 minutes once on day 1
14-day cycles
References
- ANZMTG 01.14: Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. link to original article contains verified protocol PubMed
Vemurafenib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
McArthur et al. 2017 | Phase II (RT) |
Biomarker
- BRAFV600 mutant
Chemotherapy
References
- McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol. 2017 Mar 1;28(3):634-641. link to original article PubMed